The company Novavax increased its 2025 adjusted revenue projection to $1 billion–$1.05 billion from $975 million–$1.03 billion because of better-than-expected sales from vaccine supply agreements with SK Bioscience of South Korea and Takeda of Japan. The company released the revenue update together with its quarterly results which exceeded market predictions because of a $175 million payment from U.S. approval of Nuvaxovid.
The biotech company Novavax now uses partnership agreements to bring its pipeline products to market after granting Nuvaxovid rights to Sanofi for a maximum payment of $1.2 billion. The company’s stock price increased by 4.3% before the market opened.
The FDA has requested Novavax to conduct a post-marketing study for Nuvaxovid during 2025–2026 at a $70–$90 million cost while Sanofi will cover about 70% of the expenses. The company achieved $239 million in revenue during the quarter which exceeded the predicted $148 million.
